secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vincerx Pharma, Inc. (—)
CIK:        0001796129
Form:       8-K
Filed at:   2024-03-29T23:59:59+00:00
Accession:  0001193125-24-082071
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vincerx Pharma enters $50M ATM equity offering agreement with Leerink Partners
------------------------------------------------------------------------------

- Up to $50M of common stock may be sold at-the-market through Leerink Partners as agent.
- Commission of 3.0% of gross proceeds payable to Leerink; no obligation to sell any shares.
- Sales occur under existing S-3 shelf registration (filed Jan 2022, effective Jan 2022).
- Company may suspend or terminate sales at any time; either party may terminate the agreement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1796129/000119312524082071/0001193125-24-082071-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1796129/000119312524082071/d819653d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-082071

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer